Edwards Lifesciences (NYSE:EW) Releases FY 2026 Earnings Guidance

Edwards Lifesciences (NYSE:EW) updated its FY 2026 earnings guidance on Friday. The company provided EPS guidance of 2.900-3.050 for the period, compared to the consensus EPS estimate of 2.870. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. BTIG Research reissued a “buy” rating and issued a $103.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research report on Thursday, December 4th. Wall Street Zen lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a report on Monday, November 3rd. Royal Bank Of Canada raised their target price on Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, December 5th. Finally, National Bankshares set a $92.00 price target on Edwards Lifesciences in a research report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $96.82.

Edwards Lifesciences Trading Down 0.9%

Shares of NYSE:EW opened at $83.70 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The stock’s 50-day moving average is $84.99 and its 200-day moving average is $80.80. The company has a market cap of $48.57 billion, a P/E ratio of 36.08, a P/E/G ratio of 3.22 and a beta of 0.95. Edwards Lifesciences has a 52-week low of $65.94 and a 52-week high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm’s revenue was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts predict that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,700 shares of the business’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at approximately $3,370,184.06. The trade was a 16.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total transaction of $971,384.40. Following the completion of the sale, the vice president directly owned 31,870 shares of the company’s stock, valued at approximately $2,729,984.20. This trade represents a 26.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 57,824 shares of company stock worth $4,863,323. Insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in EW. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Edwards Lifesciences by 278.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after acquiring an additional 4,108,270 shares during the period. Viking Global Investors LP acquired a new position in shares of Edwards Lifesciences in the third quarter valued at $238,688,000. AQR Capital Management LLC lifted its position in Edwards Lifesciences by 114.5% in the third quarter. AQR Capital Management LLC now owns 2,081,346 shares of the medical research company’s stock worth $161,055,000 after purchasing an additional 1,111,139 shares during the period. Man Group plc lifted its position in Edwards Lifesciences by 73.9% in the second quarter. Man Group plc now owns 1,653,939 shares of the medical research company’s stock worth $129,355,000 after purchasing an additional 702,712 shares during the period. Finally, Adage Capital Partners GP L.L.C. boosted its stake in Edwards Lifesciences by 92.8% during the second quarter. Adage Capital Partners GP L.L.C. now owns 873,817 shares of the medical research company’s stock worth $68,341,000 after buying an additional 420,551 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.